Current challenges in personalized cancer medicine
著者
書誌事項
Current challenges in personalized cancer medicine
（Advances in pharmacology / edited by Silvio Garattini [and] Parkhurst A. Shore, v. 65）
Academic Press, an imprint of Elsevier, 2012
大学図書館所蔵 全9件
注記
Includes bibliographical references and index
内容説明・目次
内容説明
For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.
目次
Vertical pathway targeting in cancer therapy
Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors
Targeting the tumor stroma as a novel treatment strategy for breast cancer - shifting from the neoplastic cell-centric to a stroma-centric paradigm
Targeting the Metabolic Microenvironment of Tumors
Targeted Therapy for Matastasis
Emerging Strategies for Targeting Cell Adhesion in Multiple Myelom
Targeting Notch Signaling for Cancer Therapeutic Intervention
Stem-like cells and therapy resistance in squamous cell carcinomas
Targeting the tumor stroma as a novel therapeutic approach for prostate cancer
Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations
Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations
Chemoprevention of Melanoma
Whole genome and exome sequencing of melanoma: a step toward personalised targeted therapy
Targeted Therapy for Gastric Adenocarcinoma
HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
Apoptosis in Targeted Therapy Responses: The Role of BIM
「Nielsen BookData」 より